Savara is a biopharmaceutical company developing MOLBREEVI, an inhaled investigational drug for a rare lung disease. It last closed at $4.48 on Nov 17, up 0.34% on the day. The average 12-month price target from 2 analysts is $11.00 (+145.5% from the last close), with a high of $12.00 and a low of $10.00.
Only 2 firms rated SVRA in the past 90 days, not enough for a consensus
Average 12-month target
$11.00
▲ 145.5% upside
Based on 2 analysts who set a price target on SVRA in the past 90 days. The average target is $11.00, with a high of $12.00 and a low of $10.00, compared with the last close of $4.48.
Low $10.00Avg $11.00High $12.00
Blue marker: last close $4.48
Highest target$12.00
Average target$11.00
Lowest target$10.00
Latest rating changes
HC Wainwright & Co.Assumed coverage
Nov 12Buy$10
JP MorganInitiated
Oct 7Buy$12
Date
Firm
Action
Rating
Price target
Nov 12
HC Wainwright & Co.
Assumed coverage
Buy
$10
Oct 7
JP Morgan
Initiated
Buy
$12
Loading…
Technical Analysis
SVRA · as of the Nov 17 close · updated after every close
Downtrend
The stock is 5% below its 20 day and 9% below its 50 day average. It is 19% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 43). The nearest support is the swing low (Oct 16) at $4.44, and the nearest resistance the Pivot R1 at $4.60.
Short trendBearish
Long trendBearish
MomentumWeak
StretchNormal
VolatilityHigh, 6.7%/day
Key levels
$7.0152 week high+56.5%
$5.32200 day average+18.8%
$5.27100 day average+17.6%
$4.99Swing high (Oct 20)+11.4%
$4.9050 day average+9.4%
$4.7120 day average+5.1%
$4.60Pivot R1+2.7%
$4.48Pivot+0.0%
$4.48Last close
$4.44Swing low (Oct 16)−0.9%
$4.35Pivot S1−2.9%
$4.1352 week low−7.8%
Indicators
RSI (14)
42.80
Middle of its range
Neutral
MACD
-0.07
Below its signal line
Bearish
Stochastic
23.1
Middle of its range
Neutral
ADX (14)
15.0
No clear trend
Williams %R
-82.4
Oversold below −80, overbought above −20
Oversold
CCI (20)
-98.6
Oversold below −100, overbought above 100
Neutral
Rate of change
−5.7%
Change over 10 sessions
Bearish
ATR (14)
$0.30
Typical daily range, 6.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Pullback inside a longer uptrend
Short trendBearish
Long trendBullish
MomentumWeak
StretchNormal
VolatilityNormal, 12.9%/day
Key levels
$7.0152 week high+56.5%
$5.32200 day average+18.8%
$5.27100 day average+17.6%
$4.99Swing high (Oct 20)+11.4%
$4.9050 day average+9.4%
$4.7120 day average+5.1%
$4.60Pivot R1+2.7%
$4.48Pivot+0.0%
$4.48Last close
$4.44Swing low (Oct 16)−0.9%
$4.35Pivot S1−2.9%
$4.1352 week low−7.8%
Indicators
RSI (14)
40.92
Middle of its range
Neutral
MACD
-0.21
Below its signal line
Bearish
Stochastic
29.1
Middle of its range
Neutral
ADX (14)
15.0
No clear trend
Williams %R
-78.0
Oversold below −80, overbought above −20
Neutral
CCI (20)
-112.7
Oversold below −100, overbought above 100
Oversold
Rate of change
−15.5%
Change over 10 sessions
Bearish
ATR (14)
$0.58
Typical daily range, 12.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Above
MA 200Above
What happened before, for SVRA
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how SVRA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow SVRA usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How SVRA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2017.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether SVRA is in one of them and how their past SVRA trades turned out.
Savara is a biopharmaceutical company that develops treatments for rare respiratory diseases. Its main product candidate, MOLBREEVI, is an investigational inhaled drug for patients with autoimmune pulmonary alveolar proteinosis, a rare lung disease in which a substance called surfactant builds up in the air sacs of the lungs. The drug is given through a nebulizer device and is not yet approved for sale. The company is based in Austin, Texas.